Contributors
-
TwentyTwentyTweets
- 2/2 ... and what does "winning" against terrorism look like to the 81 families? #PrayForManchester ...Is grief the… twitter.com/i/web/status/8… 32 minutes ago
- Two standouts from The Sage today: the ambulances were ALREADY THERE when people got outside the arena… twitter.com/i/web/status/8… 36 minutes ago
- And to all the locals who responded with kindness... thinking of all families affected #PrayForManchester #NHS… twitter.com/i/web/status/8… 23 hours ago
-
Recent Posts
Pages
Category Archives: competition
Health Tech and You Award Shortlist is Announced!
Partnered with AXA PPP healthcare and the Design Museum we are proud to announce the 2017 Health Tech and You Awards shortlist! Following the success of the previous two annual awards we have seen some of the best new forms … Continue reading
Posted in competition, Global Health, Health and Wellbeing, NHS, Public Health
Tagged digital health, health tech, Health Tech & You
Leave a comment
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: The NHS needs outstanding management as well as a legal framework, for example, to unlock the potential of the property portfolio.
The potential for improved efficiency in delivering effective healthcare within the framework of the Health and Social Care Act 2012 is enormous. However, there will be no benefit without the management skills needed to take up the challenges. Many future … Continue reading
Posted in CCGs, Commissioning, competition, Department of Health, Election, Employment, GPs, Health Bill, Health Team, Healthcare, Hospitals, Information, NHS, Nursing, Uncategorized
Tagged 2020health, Commissioning, Department of Health, Drugs, elderly, General practitioner, GPs, health, Health Bill, National Health Service, NHS, Old age, outcomes, R&D, Responsibility in healthcare, Social Care
2 Comments
Guest Blogspot: Pharmaceutical R & D – the value of radical innovation versus incremental progress
What we really want is affordable products that benefit patients, whether or not they are “innovative” in the usual sense of the word. Scientific innovation is not a medical end in itself. The ultimate aim of pharmaceutical R&D is to … Continue reading
Posted in Business, competition, Department of Health, Drugs, Emerging technologies, Finance, Healthcare, Innovation, NHS, Patients, Pharma, Policy, Research, Technology, Uncategorized
Tagged 2020health, Alderlin, angina, atenolol, beta-blocker, cimetidine, competition, David Jack, definition of innovation, Department of Health, Drugs, Eraldin, government, heart drug, incremental, Inderal, innovation, innovative, James Black, medicine, Michael Rawlins, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, practolol, pricing, pronethalol, propranolol, R&D, ranitidine, Research, Sir David Jack, Sir James Black, Sir Michael Rawlins, Tagamet, Tenormin, ulcer drug, value-based, value-based pricing, Zantac
Leave a comment
The Health and Social Care Bill: Final Stages in Parliament
With opposition to the Health and Social Care Bill having reached new heights, we must look behind the rhetoric and remember basic principles. The most important point to remember is that the NHS exists to provide the best possible, affordable … Continue reading
Posted in Andrew Lansley, Business, Commissioning, competition, David Cameron, Department of Health, GPs, Health Bill, Hospitals, Inequality, NHS, Patient choice, Patients
Tagged 2020health, Andrew Lansley, Bevan, BMA, bureaucracy, Commissioning, competition, David Cameron, Department of Health, efficiency, government, GP, GPs, health, Health Bill, inaccurate media, National Health Service, NHS, NICE, Nye Bevan, Old age, patient, Patients, Responsibility in healthcare
Leave a comment
